3 November 2022
EMA/CAT/822776/2022
Human Medicines Division

Committee for Advanced Therapies (CAT)

Minutes of the meeting on 05-07 October 2022

Chair: Martina Schuessler-Lenz; Vice-Chair: Ilona Reischl

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in these minutes are considered commercially confidential or sensitive and therefore not disclosed. Regarding intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, these minutes are a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

The Chairperson opened the meeting by welcoming all participants. Due to the coronavirus (COVID-19) outbreak, and the associated EMA Business Continuity Plan (BCP), the meeting was held remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some Committee members, alternates and experts for concerned agenda points.

Participants were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared. Restrictions applicable to this meeting are captured in the list of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

The Chair thanked the departing member, Romaldas Maciulaitis, for his contributions to the Committee.

1.2. Adoption of agenda

The CAT agenda for 05-07 October 2022 meeting was adopted.

1.3. Adoption of the minutes

The CAT minutes for 07-09 September 2022 meeting were adopted.

2. Evaluation of ATMPs

2.1. Opinions

2.1.1. Tabelecleucel - PRIME - Orphan - EMEA/H/C/004577

Atara Biotherapeutics Ireland Limited; Treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV^+ PTLD)

Scope: Opinion

Action: for adoption

List of questions adopted on 18.03.2022; List of outstanding issue adopted on 09.09.2022.

The rapporteurs presented the outcome of the assessment of the responses to the list of outstanding questions. CAT discussed the specific obligations and the product information.

CAT agreed that the benefit-risk in the indication as in the SmPC (section 4.1) is positive and that an authorisation under exceptional circumstances can be recommended. The draft opinion was adopted. Norway was in agreement with the draft opinion. The draft opinion will be forwarded to CHMP for adoption.

2.2. Oral explanations

No items

2.3. Day 180 list of outstanding issues

2.3.1. Etranacogene dezaparvovec - PRIME - Orphan - EMEA/H/C/004827

CSL Behring GmbH; Treatment of adults with Haemophilia B

Scope: Day 180 list of outstanding issues

Action: for adoption

List of questions adopted on 15.07.2022.

The rapporteurs presented the outcome of the assessment of the responses to the list of questions.

CAT adopted the list of outstanding issues.

2.4. Day 120 list of questions

No items

2.5. Day 80 assessment reports

No items

2.6. Update on ongoing initial applications

No items

2.7. New applications

2.8. Withdrawal of initial marketing authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2)

of Regulation No. 726/2004

No items

2.10. GMP and GCP inspections requests

No items

2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

2.11.1. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0003

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli

Scope: Quality.

Request for supplementary information

Action: for adoption

Request for supplementary information adopted on 15.07.2022.

The rapporteur informed CAT of the open issue . The second request for supplementary information was adopted.

2.11.2. Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0057

Amgen Europe B.V.

Rapporteur: Maija Tarkkanen

Scope: Safety. Opinion

Update to sections 4.4 and 4.8 of the SmPC to revise the safety instructions regarding the risk of disseminated herpetic infection adverse drug reactions following an MAH review of aggregate safety data of herpetic and disseminated herpetic infections that were reported in patients who were not immunocompromised and those who were immunocompromised. The Package Leaflet is updated accordingly.

Action: for adoption

The opinion was adopted.

2.11.3. Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090/II/0053

Novartis Europharm Limited

Rapporteur: Rune Kjeken

Scope: Clinical. Opinion

Submission of the final report from study CCTL019H2301 (BELINDA) listed as an obligation

in the annex II of the Product Information. This is a randomised open-label parallel-group multicentre Phase III trial to evaluate the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory B-cell aggressive NHL after failure of rituximab and anthracycline containing first-line immune-chemotherapy. The annex II is updated accordingly.

Action: for adoption

Request for supplementary information adopted on 13.05.2022.

The rapporteur presented the assessment of the response to the request for supplementary information. CAT agreed to remove the specific obligation (Annex II condition) related to the submission of the results of the Belinda study in second line NHL . The MAH will submit the final study report of the Belinda study .

The opinion was adopted.

2.11.4. Kymriah - tisagenlecleucel - Orphan - EMEA/H/C/004090/II/0059

Novartis Europharm Limited

Rapporteur: Rune Kjeken

Scope: Safety and efficacy. Opinion

Update of section 5.1 of the SmPC based on a subgroup analysis from CCTL019B2401 (B2401) disease registry listed as a PAES (ANX006) in the annex II; this is a non-interventional study to evaluate the efficacy and safety of Kymriah in acute lymphoblastic leukaemia (ALL) patients below the age of 3 years. In addition, the MAH took the opportunity to update annex II.D of the SmPC to reflect the fulfilment of the PAES.

Action: for adoption

Request for supplementary information adopted on 15.07.2022.

The rapporteur presented the assessment of the response to the request for supplementary information. CAT discussed the wording of the product information and agreed with the inclusion of overall survival data in patients below the age of 3 (data from real world evidence) in section 5.1.

The opinion was adopted.

2.12. Extension applications

No items

2.13. Other Post-Authorisation Activities

2.13.1. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/REC/002

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli, CHMP Coordinator: Armando Genazzani

Scope: Quality

Action: for adoption

The assessment of this recommendation was adopted.

2.13.2. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/REC/003

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli

Scope: Quality

Action: for adoption

The assessment of this recommendation was adopted.

2.13.3. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/REC/011

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli

Scope: Quality

Action: for adoption

The assessment of this recommendation was adopted.

2.13.4. Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/REC/012

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli

Scope: Quality

Action: for adoption

The assessment of this recommendation was adopted.

2.13.5. Luxturna - voretigene neparvovec - Orphan - EMEA/H/C/004451/REC/009

Novartis Europharm Limited

Rapporteur: Sol Ruiz

Scope: Quality

Action: for adoption

The assessment of this recommendation was adopted.

2.13.6. Upstaza - eladocagene exuparvovec - Orphan - EMEA/H/C/005352/SOB/002

PTC Therapeutics International Limited

Rapporteur: Maura O'Donovan

Scope: Study PTC-AADC-MA-406: a real-world, multicentre, observational and longitudinal study of patients with aromatic L amino acid decarboxylase (AADC) deficiency and with a severe phenotype treated with Upstaza globally, based on data from a registry, according to an agreed protocol. From initial MAA.

Action: for adoption

The rapporteur presented the review of the protocol of the Study PTC-AADC-MA-406, which is acceptable provided that the MAH provides satisfactory responses to the other concerns.

3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinion

No items

3.2. Day 60 Evaluation Reports

No items

3.3. New Applications

No items

4. Scientific Recommendation on Classification of ATMPs

Timetable:

Start of the procedure:	07.10.2022
EMA coordinator's draft report:	21.10.2022
CAT coordinator's comments:	26.10.2022
Revised scientific recommendation:	28.10.2022
CAT's discussion of scientific recommendation:	04.11.2022

4.1. New requests – Appointment of CAT Coordinator

4.1.1. Allogeneic adipose-derived mesenchymal stem cells (ADMSCs)

Intended for the treatment of osteoarthritis of the knee and hip

Scope: appointment of CAT coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.2. Day 30 ATMP scientific recommendation

4.2.1. Allogeneic adipose derived mesenchymal stem cells

Intended for the treatment of Crohn-related perianal fistula

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 21 October 2022.

4.2.2. Autologous adipose derived mesenchymal stem cells

Intended for the treatment of Crohn-related perianal fistula

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 21 October 2022.

4.2.3. Autologous anti-BCMA CAR-T cells

Intended for the treatment of multiple myeloma

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 21 October 2022.

4.2.4. Allogeneic latency-2 Epstein-Barr virus-targeted cytotoxic T lymphocytes

Intended for the treatment of multiple sclerosis

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 21 October 2022.

4.2.5. E1-deleted (replication defective) recombinant human adenovirus serotype 5 expressing TIMP3 (tissue inhibitor of metalloproteinases-3) under the control of the cytomegalovirus immediate early promoter

Intended for the treatment of coronary artery disease requiring artery bypass grafting (CABG)

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 21 October 2022.

4.2.6. Autologous CD34+ cells transfected with a lentiviral vector containing codon-optimised RPS19 gene

Intended for the treatment of transfusion-dependent, steroid-resistant paediatric patients with Diamond-Blackfan anaemia, who have a mutation in the RPS19 gene

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 21 October 2022.

4.3. Day 60 revised scientific recommendation (following list of questions)

No items

4.4. Finalisation of procedure

4.4.1. Autologous cultured limbal epithelial and limbal epithelial stem cells growing on fibrin scaffold

Intended for the treatment of moderate to severe limbal stem cell deficiency (LSCD) caused by burns, including chemical burns to the eyes

Scope: The European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

The ATMP classification report was adopted. The product does fulfil the definition of a tissue engineered product as defined in Article 2(1) of Regulation (EC) 1394/2007. The status of fibrin scaffold and its relevance for classification as combined / not combined ATMP was not considered in this recommendation.

4.4.2. Human allogeneic cardiac progenitor cell subpopulation selected for the absence of the surface marker CD90

Intended to improve cardiac perfusion and function in patients with refractory angina

Scope: The European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

The ATMP classification report was adopted. The product does fulfil the definition of a tissue engineered product as defined in Article 2(1) of Regulation (EC) 1394/2007.

4.4.3. Allogeneic CD33-directed genetically modified T-cell immunotherapy

Intended for the treatment of patients with CD33-positive acute myeloid leukaemia (AML) who are at a high risk of relapse

Scope: The European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

The ATMP classification report was adopted. The product does fulfil the definitions of a somatic cell therapy medicinal product and a gene therapy medicinal product and based on that is considered as gene therapy medicinal product as provided in Article 2(5) of Regulation (EC) No 1394/2007.

4.4.4. Allogeneic CRISPR/Cas9-edited hematopoietic stem and progenitor cells (HSPCs) lacking CD33 protein expression

Intended for the treatment of patients with CD33-positive acute myeloid leukaemia (AML) who are at a high risk of relapse

Scope: The European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

The ATMP classification report was adopted. The product does fulfil the definition of a somatic cell therapy medicinal product as defined in Article 2(1) of Regulation (EC) 1394/2007.

4.5. Follow-up and guidance

4.5.1. Ex-vivo expanded allogeneic human corneal epithelial cells containing P63 positively expressing cells

Intended for the treatment of persistent corneal epithelial defects

Scope: Updated ATMP scientific recommendation

Action: for adoption

The report has been updated following a request for clarification received from the applicant. The outcome of the ATMP classification was not changed (see August 2022 CAT minutes).

5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests - appointment of CAT Rapporteurs

5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers

Timetable:

Start of procedure at SAWP:	26-29.09.2022
Appointment of CAT peer reviewers:	05-07.10.2022
SAWP first reports:	17.10.2022
CAT peer reviewer comments (NC,C):	21.10.2022
CAT peer reviewer comments (Q):	26.10.2022
Discussion at SAWP:	24-27.10.2022
Discussion at CAT and feedback to SAWP:	04.11.2022

5.1.2. Scientific advice procedures starting at the next SAWP meeting

Timetable:

Start of procedure at SAWP:	24-27.10.2022
Appointment of CAT peer reviewers:	03-04.10.2022
SAWP first reports:	21.11.2022
CAT peer reviewer comments:	25.11.2022
Discussion at SAWP:	30.11.2022
Discussion at CAT and feedback to SAWP:	01.12.2022

5.2. Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs

5.3. Finalisation of D70 procedures – feedback from the discussion meeting

5.4. Final Advice Letters for procedures finalised the previous month

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

Timetable for assessment:	
Procedure start:	26-29.09.2022
SAWP recommendation:	27.10.2022
CAT recommendation:	04.11.2022
CHMP adoption of report and final recommendation:	10.11.2022

No items

6.3.2. Month 1 – Discussion of eligibility

No items

6.3.3. Month 2 – Recommendation of eligibility

6.3.4. Ongoing support

No items

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

No items

7.1.2. Vote by proxy

No items

7.1.3. CAT Strategic Review & Learning meeting (SRLM) under the Czechia presidency, 17 – 18 November 2022 in Paris

CAT: Petr Soukup, Martina Schuessler-Lenz

Scope: updated agenda content

Action: for discussion

The updated agenda of the upcoming SRLM was presented.

7.1.4. Update on procedure for Chair election

Action: for information

EMA presented the procedure for the election of the Chair (in January 2023) and Vice-chair (in February 2023).

7.2. Coordination with EMA Scientific Committees

7.2.1. Guideline on Safety and Efficacy Follow-up and RMP

CAT: Martina Schuessler-Lenz / Ilona Reischl

Scope: Proposal to replace current guideline

Action: for discussion

CAT agreed with the proposal. Maura O'Donovan, Concetta Quintarelli and Kerstin Sollerbrant agreed to take part in this activity. This topic will be added to the CAT workplan for 2023.

7.2.2. Scientific coordination board

CAT: Martina Schuessler-Lenz

Scope: oral feedback

Action: for information

The CAT chair provided a short feedback from the discussions in the last Scientific coordinator board meeting that took place on 30 September 2022.

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. Reflection paper on criteria to be considered for the evaluation of new active substance (NAS) status of biological substances

Rapporteur: Martijn van der Plas

Action: For adoption

The rapporteur presented the final version of the NAS reflection paper.

CAT adopted the reflection paper for a 6-month public consultation.

7.4. Cooperation with the EU regulatory network

7.4.1. Regulatory & scientific conference on RNA-based medicines

Scope: Draft agenda of the conference that is scheduled to take place on 2 February 2023.

Action: for discussion

The draft agenda was presented. The meeting will be chaired by Sol Ruiz and EMA's chief medical officer . CAT members were asked to provide suggestions of academic speakers to be invited to this conference.

7.4.2. Revision of the EU legislation on blood, tissues and cells (BTC)

CAT: Ilona Reischl

Scope: Analysis of the BTC proposal by a CAT member

Action: for information

A CAT member presented an analysis of the proposed regulation on substances of human origin (SoHO). According to this analysis, the broad definition of 'processing' will have as a consequence that some products currently defined as ATMPs and that are produced in a hospital would be considered SoHOs (and no longer as ATMPs regulated under the pharmaceutical framework).

Some CAT members acknowledged this interpretation.

7.5. Cooperation with international regulators

7.5.1. ATMP cluster teleconference with US-FDA, Health Canada and PMDA (Japan)

CAT: Martina Schuessler-Lenz

Scope: Agenda of the teleconference of 20 October 2022

Action: for information

The agenda of the ATMP cluster teleconference was presented.

7.5.2. WHO approach towards the development of a global regulatory framework for cell and gene therapy products

CAT: Ilona Reischl

Scope: Comments from the public consultation

Action: for information

Ilona Reischl provided information on the progress of the development of this WHO paper.

7.6. CAT work plan

7.6.1. CAT Workplan for 2023

CAT: Martina Schuessler-Lenz

Scope: first reflections on CAT workplan topics for 2023

Action: for discussion

A first discussion took place on the topics for the 2023 workplan. CAT members were asked to provide their input on (1) topics from the 2022 CAT workplan that should be taken forward in the 2023 workplan (including corrections to the list of contributors), and (2) any new topics for the 2023 workplan.

7.7. Planning and reporting

No items

7.8. Others

7.8.1. Adeno-associated viral (AAV) vector toxicities: regulatory considerations

CAT: Carla Herberts, Egbert Flory

Scope: Discussion paper on insertional mutagenesis and follow-up for AAV gene therapy

Action: for adoption

The changes to the document were presented. Small additional changes were proposed. The discussion paper was adopted and will now be sent to the non-clinical working party (NcWP) for comments. Thereafter it will be circulated more broadly to CHMP, PRAC and SAWP.

There was a short discussion how to make the discussion paper public (once the comments from the NcWP have been received). Publication of the discussion paper in a scientific journal and/or on the EMA website will be considered. The recommendation of duration of follow-up will be presented at the CAT regulatory session at the ESGCT meeting on 14 October 2022.

7.8.2. DARWIN EU Coordination Centre

Scope: Follow up on real world evidence (RWE) and DARWIN EU®

Action: for discussion

An update was provided on DARWIN EU® establishment and use of RWE, and the available standard analyses. There was an exchange on how CAT can request studies using DARWIN EU®.

7.8.3. Update on Clinical Trials Raw Data pilot

Scope: Presentation of the clinical trial raw data pilot

Action: for information

This pilot was presented to CAT a year ago: with this presentation an update was presented. The pilot aims to assess the benefits and practicalities of access to raw data in the assessment of medicines. The pilot, expected to last up to two years, is expected to include 10 regulatory procedures submitted to EMA from September 2022. Recent developments around EMA's raw data pilot and next steps were presented.

7.8.4. EMA Pilot – enhanced support to academic and non-profit ATMP developers

Scope: Question and answer on the pilot

Action: for discussion

EMA web announcement (29.09.2022)

EMA pilot offers enhanced support to academic and non-profit developers of advanced therapy medicinal products | European Medicines Agency (europa.eu)

EMA presented the pilot and provided some further clarifications, especially on the interplay with the activities led by the innovation offices of the NCAs that are also supporting academic developers. It was clarified that this pilot is not replacing any of the existing support mechanism for academia, but should be seen as complementary.

A question-and-answer document and the practicalities of the procedure are under development and will be shared with the NCAs when ready.

It was also confirmed that in the case where a NCA is approached by an academic developer with a potential candidate product for the pilot, the developers can be directed to EMA via the mailbox: advancedtherapies@ema.europa.eu. Alternatively, the NCAs can take the lead and coordinate the first interactions with the developer with the aim to explore the potential of the candidate product.

8. Any other business

No items

Date of next CAT meeting:

03-04/11/2022

9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Abbreviations / Acronyms

AAV: Adeno-Associated Virus

AR: Assessment Report

ATMP: Advanced Therapy Medicinal Product

BWP: Biologics Working Party

CAT: Committee for Advanced Therapies

CHMP: Committee for Medicinal Product for Human Use

COMP: Committee for Orphan Medicinal Products

CTFG: Clinical Trial Facilitation Group

DG: Drafting Group

EC: European Commission

EU NTC: European Union Network Training Centre

ERA: Environmental Risk Assessment

FDA: Food and Drug Administration

FL: Final Letter

GCG: Guideline Consistency Group

GCP: Good Clinical Practice

GLP: Good Laboratory Practice

GMO: Genetically-modified organism

GMP: Good Manufacturing Practice

GTMP: Gene Therapy Medicinal Product

HTA: Health Technology Assessment Bodies

HSPC: Hematopoietic Stem and Progenitor Cells

ITF: Innovative Task Force

JR: Joint Report

LoOI: List of outstanding issues

LoQ: List of questions

MA: Marketing Authorisation

MAA: Marketing Authorisation Application

MAH: Marketing Authorisation Holder

MNAT: Multinational assessment team

MSC: Mesenchymal stem cells

PDCO: Paediatric Committee

PMDA: Pharmaceuticals and Medical Devices Agency (Japan)

PIP: Paediatric Investigation Plan

PL: Package leaflet

PRAC: Pharmacovigilance and Risk Assessment Committee #

PRIME: Priority Medicines

QRD: Quality review of documents

RMP: Risk Management Plan

RP: Reflection paper

RSI: Request for supplementary information

SAs: Scientific Advices

SAG-O: Scientific Advisory Group Oncology

SAWP: Scientific Advice Working Party

SR: Summary Report

SWP: Safety Working Party

SME: Small and medium size enterprises

SmPC: Summary of Products Characteristics

TT: Timetable

Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists any ATMP related inspection requests (section 2.9) and Post-authorisation activities (section 2.10).

New applications (sections 2.1. to 2.12.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found here.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.3) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures**). Section 2.7 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.6.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Withdrawal of applications (section 2.7.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

New applications (section 2.9.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

GMP and GCP Inspections Issues (section 2.10.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Post-authorisation activities (section 2.12.)

This section lists type II variations, extension application according to Annex I of Reg. 1234/2008, re-examination procedures for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP and other issues concerning authorised medicines that are not covered elsewhere in the agenda such as annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found here.

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found here.

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found here.

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found here.

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

10. List of participants

Including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 05-07 October 2022 meeting.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Martina Schüssler-Lenz	Chair	Germany	No interests declared	
Ilona Reischl	Member (Vice-Chair)	Austria	No interests declared	
Silke Dorner	Alternate	Austria	No interests declared	
Claire Beuneu	Member	Belgium	No interests declared	
Belaïd Sekkali	Alternate	Belgium	No interests declared	
Evelina Shumkova	Alternate	Bulgaria	No interests declared	
Azra Selimovic	Member	Croatia	No interests declared	
Rafaella Pontou	Member	Cyprus	No interests declared	
Isavella Kyriakidou	Alternate	Cyprus	No interests declared	
Petr Soukup	Member	Czechia	No interests declared	
Kristyna Rehorova Hradilkova	Alternate	Czechia	No interests declared	
Ebru Karakoc Madsen	Member	Denmark	No restrictions applicable to this meeting	
Toivo Maimets	Member	Estonia	No interests declared	
Pille Saalik	Alternate	Estonia	No interests declared	
Heli Suila	Member	Finland	No interests declared	
Violaine Closson	Member	France	No interests declared	
Jean-Michel Race	Alternate	France	No interests declared	
Egbert Flory	Alternate (to CHMP representative)	Germany	No interests declared	
Maria Gazouli	Member	Greece	No interests declared	
Angeliki Rompoti	Alternate	Greece	No interests declared	
Katalin Lengyel	Member	Hungary	No interests declared	
Maura O'Donovan	Member	Ireland	No interests declared	
Niamh Curran	Alternate	Ireland	No restrictions applicable to this meeting	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Concetta Quintarelli	Member	Italy	No interests declared	
Barbara Bonamassa	Alternate	Italy	No participation in discussions, final deliberations and voting on:	**4.4.2.** Oloker Therapeutics S.r.l.; Intended to improve cardiac perfusion and function in patients with refractory angina;
Una Riekstina	Member	Latvia	No interests declared	
Raimondas Benetis	Alternate (to CHMP representative)	Lithuania	No interests declared	
Guy Berchem	Alternate	Luxembourg	Cannot act as rapporteur, other leading/co-ordinating role or peer reviewer for:	
Nancy De Bremaeker	Member	Luxembourg	No interests declared	
Anthony Samuel	Alternate (to CHMP representative)	Malta	No interests declared	
Carla Herberts	Member	Netherlands	No interests declared	
Babs Fabriek	Alternate	Netherlands	No interests declared	
Rune Kjeken	Member	Norway	No restrictions applicable to this meeting	
Dariusz Śladowski	Member	Poland	No restrictions applicable to this meeting	
Maria Isabel Borba Vieira	Alternate (to CHMP representative)	Portugal	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Silviu Istrate	Member	Romania	No interests declared	
Katarina Vavrová	Alternate	Slovakia	No interests declared	
Metoda Lipnik-Stangelj	Member	Slovenia	No interests declared	
Suzana Vidic	Alternate	Slovenia	No participation in final deliberations and voting on:	**2.11.3. Kymriah** - tisagenlecleucel - Orphan - EMEA/H/C/004090/II/0053 Novartis Europharm Limited; **2.11.4. Kymriah** - tisagenlecleucel - Orphan - EMEA/H/C/004090/II/0059 Novartis Europharm Limited; **2.13.5. Luxturna** - voretigene neparvovec - Orphan - EMEA/H/C/004451/REC/009 Novartis Europharm Limited
Marcos Timón	Alternate (to CHMP representative)	Spain	No interests declared	
Lisbeth Barkholt	Member	Sweden	No interests declared	
Maria Luttgen	Alternate	Sweden	No restrictions applicable to this meeting	
Bernd Gänsbacher	Alternate	Clinicians' Representative	No interests declared	
Paolo Gasparini	Member	Clinicians' Representative	No interests declared	
Alessandro Aiuti	Member	Clinicians' Representative	Cannot act as rapporteur, other leadin/co-ordinating role or peer reviewer for:	
Alessandra Renieri	Alternate	Clinicians' Representative	No restrictions applicable to this meeting	
Kerstin Sollerbrant	Member	Patients' Representative	No interests declared	
Kieran Breen	Member	Patients' Representative	No interests declared	
Federica Chiara	Alternate	Patients' Representative	No restrictions applicable to this meeting	
Brigitte Mueller	Expert via Webex	AGES (AT)	No interests declared	
Harald Bernsteiner	Expert via Webex	AGES (AT)	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Melanie Ramberger	Expert via Webex	AGES (AT)	No interests declared	
Susana Rojo Gozalo	Expert via Webex	AEMPS (ES)	No interests declared	
Paloma Mas	Expert via Webex	AEMPS (ES)		
Enrico Costa	Expert via Webex	COMP(IT)	No interests declared	
Hans Ovelgonne	Expert via Webex	SAWP (NL)	No interests declared	
Martijn Van der Plas	Expert via Webex	CBG-MEB (NL)		
Karri Penttila	Expert via Webex	COMP (FI)	No interests declared	
Hanna Kankkonen	Expert via Webex	FIMEA (FI)	No interests declared	
Johanna Lähteenvuo	Expert via Webex	SAWP(FI)	No interests declared	
Thomas Hinz	Expert via Webex	PEI (DE)	No interests declared	
Verena Scheer	Expert via Webex	PEI (DE)	No interests declared	
Zuzana Jedlicková	Expert via Webex	PEI (DE)	No interests declared	
Astrid Schwantes	Expert via Webex	PEI (DE)	No interests declared	
Antonella Isgro	Expert via Webex	PEI (DE)	No interests declared	
A representative from the European Commission attended the meeting				
Meeting run with support from relevant EMA staff				